AbbVie Stock (NYSE:ABBV)
Previous Close
$169.63
52W Range
$137.14 - $207.32
50D Avg
$192.61
200D Avg
$178.95
Market Cap
$291.56B
Avg Vol (3M)
$5.19M
Beta
0.61
Div Yield
$6.56 (4.70%)
ABBV Company Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Botox Therapeutic | $2.99B | $2.72B | - |
| Other Neuroscience | $276.00M | $475.00M | - |
| Qulipta | $408.00M | - | - |
| Ubrelvy | $815.00M | - | - |
| Vraylar | $2.76B | $2.04B | - |
| Linzess/Constella | $1.11B | $1.03B | - |
| MAVYRET | $1.43B | $1.54B | - |
| Other Products | $3.04B | $4.14B | $2.67B |
| SKYRIZI | $7.76B | $5.17B | - |
| RINVOQ | $3.97B | $2.52B | - |
| H U M I R A | $14.40B | $21.24B | - |
| VENCLEXTA | $2.29B | $2.01B | - |
| Imbruvica | $3.60B | $4.57B | - |
| Restasis | $436.00M | $666.00M | - |
| Ozurdex | $472.00M | - | - |
| Other Eye Care | $803.00M | $1.18B | - |
| Lumigan/Ganfort | $432.00M | $514.00M | - |
| Alphagan/Combigan | $272.00M | $346.00M | - |
| Other Aesthetics | $1.23B | $1.29B | - |
| Juvederm Collection | $1.38B | $1.43B | - |
| Botox Cosmetic | $2.68B | $2.62B | - |
| Duodopa | $468.00M | $458.00M | - |
Fiscal year ends in Dec 23 | Currency in USD